<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; needs</title>
	<atom:link href="http://www.tapanray.in/tag/needs/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Meeting India’s Unmet Biologic Drug Needs Some Global Synergy Evident &#8211; But Patients Need More</title>
		<link>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more</link>
		<comments>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/#comments</comments>
		<pubDate>Mon, 17 Jul 2023 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[Biosimilar. drugs]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10799</guid>
		<description><![CDATA[Many reports have vindicated the rapidly growing importance of biologic drugs in the treatment of a wide range of complex ailments. These include autoimmune diseases, cancers, hormonal irregularities, anemia, and to prevent various diseases such as vaccines, have drawn healthcare &#8230; <a href="http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fostering EQ For Pharma’s Excellence In The New Normal</title>
		<link>http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fostering-eq-for-pharmas-excellence-in-the-new-normal</link>
		<comments>http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 01 Mar 2021 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[cutting-edge]]></category>
		<category><![CDATA[disruption]]></category>
		<category><![CDATA[EI]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[EQ]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[quotient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[sign]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[telltale]]></category>
		<category><![CDATA[unprecedented]]></category>
		<category><![CDATA[workplace]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10427</guid>
		<description><![CDATA[On February 25, 2021, one of the top Indian business daily flashed a headline &#8211; “It will be working from home, post-pandemic too at many top companies.” It wrote, companies like, Tata Steel, Philips, Infosys and Maruti Suzuki are evaluating job roles to &#8230; <a href="http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spirit Behind Drug Patent Grant: Secondary Patents: Impact on Drug Access</title>
		<link>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access</link>
		<comments>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/#comments</comments>
		<pubDate>Mon, 09 Sep 2019 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents Act]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Spirit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9701</guid>
		<description><![CDATA[For more effective treatment against existing diseases, besides combating new or a more complicated form of existing ailments with precision, drug innovation is absolutely necessary and on an ongoing basis. This makes innovative drugs so important for the population, globally. &#8230; <a href="http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare in India And Hierarchy of Needs</title>
		<link>http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-in-india-and-hierarchy-of-needs</link>
		<comments>http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/#comments</comments>
		<pubDate>Sun, 05 Nov 2017 23:30:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ease]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hierarchy]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[Hunger]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Maslow]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[voters]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8545</guid>
		<description><![CDATA[“Russia and India climb World Bank’s Doing Business rankings”, was a headline in the Financial Times on October 31, 2017. India jumped 30 places &#8211; from 130 out of 190. Almost instantly, the domestic media flashed it all across the &#8230; <a href="http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-in-india-and-hierarchy-of-needs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Wide Gap Between Health Care Needs, And Delivery: Is The Bridge Still Too Far?</title>
		<link>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far</link>
		<comments>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/#comments</comments>
		<pubDate>Mon, 28 Dec 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[28]]></category>
		<category><![CDATA[Ayog]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[February]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[healtrh]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[wide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7353</guid>
		<description><![CDATA[“Health inequities which abound in India must be corrected through investments in a robust primary health care system,&#8221; said Professor K Srinath Reddy, chairman, Public Health Foundation of India (PHFI), not too long ago. The equity gap between health care &#8230; <a href="http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Meeting Unmet Needs of Patients”: A New Direction</title>
		<link>http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-unmet-needs-of-patients-a-new-direction</link>
		<comments>http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/#comments</comments>
		<pubDate>Mon, 27 Jan 2014 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[banal]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[evergreen]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[genomics]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Meeting]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tufts]]></category>
		<category><![CDATA[unmet]]></category>
		<category><![CDATA[warfarin]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4874</guid>
		<description><![CDATA[The much-hyped phrase of the global pharma majors &#8211; ‘meeting unmet needs of patients’, is very often used to create an aura around newer patented drugs of all kinds, from original to banal, including evergreen varieties such as: Evergreen Drug/Brand &#8230; <a href="http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-unmet-needs-of-patients-a-new-direction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Intervened…But ‘Price Control’ needs striking a right balance between ‘Affordability’ and ‘Availability’ of medicines for Patients’ Sake</title>
		<link>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients</link>
		<comments>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/#comments</comments>
		<pubDate>Mon, 08 Oct 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intervened]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicines for Patients’ Sake]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1084</guid>
		<description><![CDATA[On October 3, 2012, the Supreme Court bench of Justice GS Singhvi and Justice SJ Mukhopadhayareportedly asked the government not to disturb the existing price control mechanism while including all medicines featuring  in the National List of Essential Medicines 2011 (NLEM &#8230; <a href="http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare Tourism: India needs to step on the gas</title>
		<link>http://www.tapanray.in/healthcare-tourism-india-needs-to-step-on-the-gas/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-tourism-india-needs-to-step-on-the-gas</link>
		<comments>http://www.tapanray.in/healthcare-tourism-india-needs-to-step-on-the-gas/#comments</comments>
		<pubDate>Mon, 30 Jan 2012 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[gas]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Tourism]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=140</guid>
		<description><![CDATA[Healthcare Tourism or Medical Tourism are the terminologies initially coined by the travel agents and the media when patients travel outside their national boundaries to seek either more specialized and/or cheaper but high quality healthcare available in other countries. World &#8230; <a href="http://www.tapanray.in/healthcare-tourism-india-needs-to-step-on-the-gas/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-tourism-india-needs-to-step-on-the-gas/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India needs ‘Orphan Drugs Act (ODA)’ to counter growing threat of dreaded rare diseases and simultaneously boost global growth potential of the Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 01 Nov 2010 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[dreaded]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[simultaneous]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=354</guid>
		<description><![CDATA[An orphan disease is a rare and uncommon disease and an ‘Orphan Drug’ is a pharmaceutical substance that has been developed to treat an orphan disease. The US FDA defines a rare disease, with a prevalence of 1 in 5,000 &#8230; <a href="http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leverage the potential of ‘Telemedicine’ to effectively address the healthcare needs of India</title>
		<link>http://www.tapanray.in/leverage-the-potential-of-telemedicine-to-effectively-address-the-healthcare-needs-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leverage-the-potential-of-telemedicine-to-effectively-address-the-healthcare-needs-of-india</link>
		<comments>http://www.tapanray.in/leverage-the-potential-of-telemedicine-to-effectively-address-the-healthcare-needs-of-india/#comments</comments>
		<pubDate>Mon, 26 Jul 2010 01:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[address]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[effectively]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[primary]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[tertiary]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[urban]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=397</guid>
		<description><![CDATA[The World Health Organization (WHO) has defined telemedicine as follows: “The delivery of healthcare services, where distance is a critical factor, by all healthcare professionals using information and communication technologies for the exchange of valid information for diagnosis, treatment and &#8230; <a href="http://www.tapanray.in/leverage-the-potential-of-telemedicine-to-effectively-address-the-healthcare-needs-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leverage-the-potential-of-telemedicine-to-effectively-address-the-healthcare-needs-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
